請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69368
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林中梧(Chung-Wu Lin) | |
dc.contributor.author | Po-Ting Yeh | en |
dc.contributor.author | 葉伯廷 | zh_TW |
dc.date.accessioned | 2021-06-17T03:13:56Z | - |
dc.date.available | 2018-08-01 | |
dc.date.copyright | 2018-08-01 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-07-11 | |
dc.identifier.citation | 1. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058-1070.
2. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999;48:1-9. 3. Kaneto H, Katakami N, Kawamori D, et al. Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid Redox Signal 2007;9:355-366. 4. Pan HZ, Zhang H, Chang D, et al. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br J Ophthalmol 2008;92:548-551. 5. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19:257-267. 6. Joussen AM, Murata T, Tsujikawa A, et al. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001;158:147-152. 7. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-1452. 8. Hsieh MC, Yeh PT, Yang CM, et al. Anterior retinal cryotherapy and intravitreal injection of bevacizumab in the treatment of nonclearing vitreous hemorrhage in proliferative diabetic retinopathy. J Ocul Pharmacol Ther 2014;30:353-358. 9. Bahrami B, Hong T, Gilles MC, et al. Anti-VEGF Therapy for Diabetic Eye Diseases. Asia Pac J Ophthalmol (Phila) 2017;6:535-545. 10. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:823-833. 11. Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:834-840. 12. Royle P, Mistry H, Auguste P, et al. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation. Health Technol Assess 2015;19:v-xxviii, 1-247. 13. Benedett R, Olk RJ, Arribas NP, et al. Transconjunctival anterior retinal cryotherapy for proliferative diabetic retinopathy. Ophthalmology 1987;94:612-619. 14. Branisteanu DC, Bilha A, Moraru A. Vitrectomy surgery of diabetic retinopathy complications. Rom J Ophthalmol 2016;60:31-36. 15. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. 16. Avery RL, Castellarin AA, Steinle NC, et al. Systemic Pharmacokinetics and Pharmacodynamics of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab. Retina 2017;37:1847-1858. 17. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:11393-11398. 18. Castellarin A, Grigorian R, Bhagat N, et al. Vitrectomy with silicone oil infusion in severe diabetic retinopathy. Br J Ophthalmol 2003;87:318-321. 19. Brown GC, Tasman WS, Benson WE, et al. Reoperation following diabetic vitrectomy. Arch Ophthalmol 1992;110:506-510. 20. Michels RG. Proliferative diabetic retinopathy: pathophysiology of extraretinal complications and principles of vitreous surgery. Retina 1981;1:1-17. 21. Yang CM. Surgical treatment for diabetic retinopathy: 5-year experience. J Formos Med Assoc 1998;97:477-484. 22. Blankenship GW. Management of vitreous cavity hemorrhage following pars plana vitrectomy for diabetic retinopathy. Ophthalmology 1986;93:39-44. 23. Blumenkranz M, Gardner T, Blankenship G. Fluid-gas exchange and photocoagulation after vitrectomy. Indications, technique, and results. Arch Ophthalmol 1986;104:291-296. 24. Han DP, Murphy ML, Mieler WF, et al. Outpatient fluid-air exchange for severe postvitrectomy diabetic vitreous hemorrhage. Long-term results and complications. Retina 1991;11:309-314. 25. Chauvaud D. [Anticoagulation and vitreoretinal surgery]. Bull Acad Natl Med 2007;191:879-884. 26. Fu AD, McDonald HR, Williams DF, et al. Anticoagulation with warfarin in vitreoretinal surgery. Retina 2007;27:290-295. 27. Dayani PN, Grand MG. Maintenance of warfarin anticoagulation for patients undergoing vitreoretinal surgery. Arch Ophthalmol 2006;124:1558-1565. 28. Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology 2007;114:710-715. 29. Joondeph BC, Blankenship GW. Hemostatic effects of air versus fluid in diabetic vitrectomy. Ophthalmology 1989;96:1701-1706; discussion 1706-1707. 30. Koutsandrea CN, Apostolopoulos MN, Chatzoulis DZ, et al. Hemostatic effects of SF6 after diabetic vitrectomy for vitreous hemorrhage. Acta Ophthalmol Scand 2001;79:34-38. 31. Kim SH, Cho YS, Choi YJ. Intraocular hemocoagulase in human vitrectomy. Jpn J Ophthalmol 1994;38:49-55. 32. Crafoord S, Stenkula S. Healon GV in posterior segment surgery. Acta Ophthalmol (Copenh) 1993;71:560-561. 33. Kharrat W, Turki K, Amor HB, et al. [Use of silicone oil in vitreal hemorrhage complicating proliferated diabetic retinopathy.]. J Fr Ophtalmol 2009;32:98-103. 34. Le Mer Y. [Use of liquid perfluorocarbons in vitrectomy for difficult cases of proliferative diabetic retinopathy]. J Fr Ophtalmol 1995;18:366-372. 35. Witherspoon CD, Morris RE, Goggans WE, Jr. Automated regulation of fluid infusion pressure during vitrectomy. Arch Ophthalmol 1986;104:1551. 36. Ryan SJ, editor. Retina, fourth ed. Philadelphia: Elsevier Mosby, 2006:2451-2461. 37. McCuen BW, 2nd, Hickingbotham D. A fiberoptic diathermy tissue manipulator for use in vitreous surgery. Am J Ophthalmol 1984;98:803-804. 38. Blacharski PA, Charles ST. Thrombin infusion to control bleeding during vitrectomy for stage V retinopathy of prematurity. Arch Ophthalmol 1987;105:203-205. 39. Thompson JT, Glaser BM, Michels RG, et al. The use of intravitreal thrombin to control hemorrhage during vitrectomy. Ophthalmology 1986;93:279-282. 40. Kim SH, Lee HS, Kim IT, et al. Efficacy of intravitreal hemocoagulase for control of bleeding in rabbit experimental model of vitrectomy. Jpn J Ophthalmol 1993;37:379-384. 41. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695 e1691-1615. 42. Mason JO, 3rd, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:685-688. 43. Oshima Y, Sakaguchi H, Gomi F, et al. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:155-158. 44. Yang CM, Yeh PT, Yang CH, et al. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol 2008;146:211-217. 45. Yeh PT, Yang CM, Lin YC, et al. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina 2009;29:768-774. 46. Ishikawa K, Honda S, Tsukahara Y, et al. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye (Lond) 2009;23:108-111. 47. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006;26:699-700. 48. Arevalo JF, Maia M, Flynn HW, Jr., et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92:213-216. 49. Shen YD, Yang CM. Extended silicone oil tamponade in primary vitrectomy for complex retinal detachment in proliferative diabetic retinopathy: a long-term follow-up study. Eur J Ophthalmol 2007;17:954-960. 50. Douglas MJ, Scott IU, Flynn HW, Jr. Pars plana lensectomy, pars plana vitrectomy, and silicone oil tamponade as initial management of cataract and combined traction/rhegmatogenous retinal detachment involving the macula associated with severe proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging 2003;34:270-278. 51. Hoerauf H, Roider J, Bopp S, et al. [Endotamponade with silicon oil in severe proliferative retinopathy with attached retina]. Ophthalmologe 1995;92:657-662. 52. Oyakawa RT, Schachat AP, Michels RG, et al. Complications of vitreous surgery for diabetic retinopathy. I. Intraoperative complications. Ophthalmology 1983;90:517-521. 53. Asaria RH, Kon CH, Bunce C, et al. Silicone oil concentrates fibrogenic growth factors in the retro-oil fluid. Br J Ophthalmol 2004;88:1439-1442. 54. Lewis H, Burke JM, Abrams GW, et al. Perisilicone proliferation after vitrectomy for proliferative vitreoretinopathy. Ophthalmology 1988;95:583-591. 55. Eliott D, Lee MS, Abrams GS. Proliferative diabetic retinopathy: principles and techniques of surgical treatment., 4th ed. In: Ryan SJ, Hinton DR, Schachat AP, Wilkinson P, editors. Retina. Philadelphia: Elsevier Mosby, 2006:2413-2415. 56. de Bustros S, Glaser BM, Michels RG, et al. Effect of epsilon-aminocaproic acid on postvitrectomy hemorrhage. Arch Ophthalmol 1985;103:219-221. 57. Ramezani AR, Ahmadieh H, Ghaseminejad AK, et al. Effect of tranexamic acid on early postvitrectomy diabetic haemorrhage; a randomised clinical trial. Br J Ophthalmol 2005;89:1041-1044. 58. Packer AJ, McCuen BW, 2nd, Hutton WL, et al. Procoagulant effects of intraocular sodium hyaluronate (Healon) after phakic diabetic vitrectomy. A prospective, randomized study. Ophthalmology 1989;96:1491-1494. 59. Folk JC, Packer AJ, Weingeist TA, et al. Sodium hyaluronate (Healon) in closed vitrectomy. Ophthalmic Surg 1986;17:299-306. 60. Bodanowitz S, Kir N, Hesse L. Silicone oil for recurrent vitreous hemorrhage in previously vitrectomized diabetic eyes. Ophthalmologica 1997;211:219-222. 61. Charles S, Katz A, Wood B, editors. Vitreous Microsurgery, Third ed. Philaldelphia: Lippincott Williams & Wilkins, 2002:104-125. 62. Bhende M, Agraharam SG, Gopal L, et al. Ultrasound biomicroscopy of sclerotomy sites after pars plana vitrectomy for diabetic vitreous hemorrhage. Ophthalmology 2000;107:1729-1736. 63. Hershberger VS, Augsburger JJ, Hutchins RK, et al. Fibrovascular ingrowth at sclerotomy sites in vitrectomized diabetic eyes with recurrent vitreous hemorrhage: ultrasound biomicroscopy findings. Ophthalmology 2004;111:1215-1221. 64. Hotta K, Hirakata A, Ohi Y, et al. Ultrasound biomicroscopy for examination of the sclerotomy site in eyes with proliferative diabetic retinopathy after vitrectomy. Retina 2000;20:52-58. 65. West JF, Gregor ZJ. Fibrovascular ingrowth and recurrent haemorrhage following diabetic vitrectomy. Br J Ophthalmol 2000;84:822-825. 66. Koch FH, Kreiger AE, Spitznas M, et al. Pars plana incisions of four patients: histopathology and electron microscopy. Br J Ophthalmol 1995;79:486-493. 67. Kreiger AE. Wound complications in pars plana vitrectomy. Retina 1993;13:335-344. 68. Yeh PT, Yang CM, Yang CH, et al. Cryotherapy of the anterior retina and sclerotomy sites in diabetic vitrectomy to prevent recurrent vitreous hemorrhage: an ultrasound biomicroscopy study. Ophthalmology 2005;112:2095-2102. 69. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005;3:1894-1904. 70. Park DH, Shin JP, Kim SY. Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study. Graefes Arch Clin Exp Ophthalmol;248:641-650. 71. Faghihi H, Taheri A, Farahvash MS, et al. Intravitreal triamcinolone acetonide injection at the end of vitrectomy for diabetic vitreous hemorrhage: a randomized, clinical trial. Retina 2008;28:1241-1246. 72. Schachat AP, Oyakawa RT, Michels RG, et al. Complications of vitreous surgery for diabetic retinopathy. II. Postoperative complications. Ophthalmology 1983;90:522-530. 73. Lewis H, Ryan SJ, editors. Medical and Surgical Retina: Advances, Controversies, and Management. St. Louis: Mosby, 1994:330-340. 74. Lee SY, Yoon YH, Lee HG, et al. Intravitreal triamcinolone acetonide in eyes with recurrent postvitrectomy diabetic vitreous hemorrhage. Am J Ophthalmol 2006;142:501-503. 75. Lambrou FH, Devenyi RG, Han DP. Fluid-gas exchange after vitrectomy using long-acting gases in an outpatient setting. Arch Ophthalmol 1988;106:1344. 76. Miller JA, Chandra SR, Stevens TS. A modified technique for performing outpatient fluid-air exchange following vitrectomy surgery. Am J Ophthalmol 1986;101:116-117. 77. Ryan SJ, editor. Retina, fourth ed. Philadelphia: Elsevier Mosby, 2006:2440-2441. 78. Steel DH, Habib MS, Park S, et al. Entry site neovascularization and vitreous cavity hemorrhage after diabetic vitrectomy. The predictive value of inner sclerostomy site ultrasonography. Ophthalmology 2008;115:525-532. 79. Yeh PT, Yang CH, Yang CM. Intravitreal bevacizumab injection for recurrent vitreous haemorrhage after diabetic vitrectomy. Acta Ophthalmol 2011;89:634-640. 80. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859. 81. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814-2823. 82. Ficker L, Meredith TA, Gardner S, et al. Cefazolin levels after intravitreal injection. Effects of inflammation and surgery. Invest Ophthalmol Vis Sci 1990;31:502-505. 83. Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol 1976;81:383-396. 84. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981;88:583-600. 85. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:766-785. 86. Shimura M, Yasuda K, Nakazawa T, et al. Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 2003;110:2386-2394. 87. Schimek RA, Spencer R. Cryopexy treatment of proliferative diabetic retinopathy. Retinal cryoablation in patients with severe vitreous hemorrhage. Arch Ophthalmol 1979;97:1276-1280. 88. Mosier MA, Del Piero E, Gheewala SM. Anterior retinal cryotherapy in diabetic vitreous hemorrhage. Am J Ophthalmol 1985;100:440-444. 89. Neely KA, Scroggs MW, McCuen BW, 2nd. Peripheral retinal cryotherapy for postvitrectomy diabetic vitreous hemorrhage in phakic eyes. Am J Ophthalmol 1998;126:82-90. 90. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-278. 91. Huang YH, Yeh PT, Chen MS, et al. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. Retina 2009;29:1134-1140. 92. Curtin VT, Fujino T, Norton EW. Comparative histopathology of cryosurgery and photocoagulation. Observations on the advantages of cryosurgery in retinal detachment operations. Arch Ophthalmol 1966;75:674-682. 93. Williams DF, Burke JM, Williams GA. Clearance of experimental vitreous hemorrhage after panretinal cryotherapy is related to macrophage influx. Arch Ophthalmol 1990;108:595-597. 94. Cekic O, Batman C. Peripheral retinal cryotherapy for postvitrectomy diabetic vitreous hemorrhage in phakic patients. Am J Ophthalmol 1999;127:740-741. 95. Yeh PT, Yang CM, Yang CH. Distribution, reabsorption, and complications of preretinal blood under silicone oil after vitrectomy for severe proliferative diabetic retinopathy. Eye (Lond) 2012;26:601-608. 96. Kono T, Kohno T, Inomata H. Epiretinal membrane formation. Light and electron microscopic study in an experimental rabbit model. Arch Ophthalmol 1995;113:359-363. 97. Bringmann A, Wiedemann P. Involvement of Muller glial cells in epiretinal membrane formation. Graefes Arch Clin Exp Ophthalmol 2009;247:865-883. 98. Yamaji H, Shiraga F, Shiragami C, et al. Reduction in dose of intravitreous bevacizumab before vitrectomy for proliferative diabetic retinopathy. Arch Ophthalmol;129:106-107. 99. Abdelhakim MA, Macky TA, Mansour KA, et al. Bevacizumab (Avastin) as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Ophthalmic Res;45:23-30. 100. Hernandez-Da Mota SE, Nunez-Solorio SM. Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy. Eur J Ophthalmol;20:1047-1052. 101. Modarres M, Nazari H, Falavarjani KG, et al. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 2009;19:848-852. 102. Martinez-Castillo V, Boixadera A, Distefano L, et al. Epiretinal membrane after pars plana vitrectomy for primary pseudophakic or aphakic rhegmatogenous retinal detachment: incidence and outcomes. Retina 2012;32:1350-1355. 103. Karadimas P, Kapetanios A, Panayotidhou E, et al. Epiretinal membrane occurring with myelinated retinal nerve fibers and vascular abnormalities. Retina 2003;23:880-881. 104. Oh KT, Fammartino JJ. Epiretinal membrane formation. Retina 1996;16:346-347. 105. Okada M, Ogino N, Matsumura M, et al. Histological and immunohistochemical study of idiopathic epiretinal membrane. Ophthalmic Res 1995;27:118-128. 106. Messmer E, Bornfeld N, Oehlschlager U, et al. [Epiretinal membrane formation after pars plana vitrectomy in proliferative diabetic retinopathy]. Klin Monatsbl Augenheilkd 1992;200:267-272. 107. Kase S, Saito W, Ohno S, et al. Proliferative diabetic retinopathy with lymphocyte-rich epiretinal membrane associated with poor visual prognosis. Invest Ophthalmol Vis Sci 2009;50:5909-5912. 108. Zhao F, Gandorfer A, Haritoglou C, et al. Epiretinal cell proliferation in macular pucker and vitreomacular traction syndrome: analysis of flat-mounted internal limiting membrane specimens. Retina 2013;33:77-88. 109. Yang CM, Yeh PT, Cheng SF, et al. Macular appearance after diabetic vitrectomy for fibrovascular proliferation: an optical coherence tomography study. Acta Ophthalmol 2010;88:193-198. 110. Hosoda Y, Okada M, Matsumura M, et al. Epiretinal membrane of proliferative diabetic retinopathy: an immunohistochemical study. Ophthalmic Res 1993;25:289-294. 111. Dong Z, Kase S, Ando R, et al. Alphab-crystallin expression in epiretinal membrane of human proliferative diabetic retinopathy. Retina 2012;32:1190-1196. 112. Kase S. [Correlation with histological findings and visual prognosis in epiretinal membrane of human diabetic retinopathy]. Nippon Ganka Gakkai Zasshi 2011;115:998-1006. 113. Kase S, Saito W, Ohgami K, et al. Expression of erythropoietin receptor in human epiretinal membrane of proliferative diabetic retinopathy. Br J Ophthalmol 2007;91:1376-1378. 114. Grigorian RA, Castellarin A, Fegan R, et al. Epiretinal membrane removal in diabetic eyes: comparison of viscodissection with conventional methods of membrane peeling. Br J Ophthalmol 2003;87:737-741. 115. Messmer E, Bornfeld N, Oehlschlager U, et al. [Epiretinal membrane formation after pars plana vitrectomy in proliferative diabetic retinopathy]. Klin Monbl Augenheilkd 1992;200:267-272. 116. Hsu YR, Yang CM, Yeh PT. Clinical and histological features of epiretinal membrane after diabetic vitrectomy. Graefes Arch Clin Exp Ophthalmol 2014;252:401-410. 117. Yagi T, Sakata K, Funatsu H, et al. Evaluation of perifoveal capillary blood flow velocity before and after vitreous surgery for epiretinal membrane. Graefes Arch Clin Exp Ophthalmol 2012;250:459-460. 118. Krepler K, Polska E, Wedrich A, et al. Ocular blood flow parameters after pars plana vitrectomy in patients with diabetic retinopathy. Retina 2003;23:192-196. 119. Roldan-Pallares M, Rollin R, Mediero A, et al. Immunoreactive ET-1 in the vitreous humor and epiretinal membranes of patients with proliferative vitreoretinopathy. Mol Vis 2005;11:461-471. 120. Schoenberger SD, Kim SJ, Sheng J, et al. Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. Invest Ophthalmol Vis Sci 2012;53:5906-5911. 121. Iannetti L, Accorinti M, Malagola R, et al. Role of the intravitreal growth factors in the pathogenesis of idiopathic epiretinal membrane. Invest Ophthalmol Vis Sci 2011;52:5786-5789. 122. Abu El-Asrar AM, Missotten L, Geboes K. Expression of advanced glycation end products and related molecules in diabetic fibrovascular epiretinal membranes. Clin Exp Ophthalmol 2010;38:57-64; quiz 87. 123. Abu El-Asrar AM, Struyf S, Opdenakker G, et al. Expression of stem cell factor/c-kit signaling pathway components in diabetic fibrovascular epiretinal membranes. Mol Vis 2010;16:1098-1107. 124. Schwatz SD, Alexander R, Hiscott P, et al. Recognition of vitreoschisis in proliferative diabetic retinopathy. A useful landmark in vitrectomy for diabetic traction retinal detachment. Ophthalmology 1996;103:323-328. 125. Gandorfer A, Rohleder M, Grosselfinger S, et al. Epiretinal pathology of diffuse diabetic macular edema associated with vitreomacular traction. Am J Ophthalmol 2005;139:638-652. 126. Bovey EH, Uffer S, Achache F. Surgery for epimacular membrane: impact of retinal internal limiting membrane removal on functional outcome. Retina 2004;24:728-735. 127. Kwok AK, Lai TY, Li WW, et al. Indocyanine green-assisted internal limiting membrane removal in epiretinal membrane surgery: a clinical and histologic study. Am J Ophthalmol 2004;138:194-199. 128. Park DW, Dugel PU, Garda J, et al. Macular pucker removal with and without internal limiting membrane peeling: pilot study. Ophthalmology 2003;110:62-64. 129. Kwok A, Lai TY, Yuen KS. Epiretinal membrane surgery with or without internal limiting membrane peeling. Clin Exp Ophthalmol 2005;33:379-385. 130. Patel JI, Hykin PG, Schadt M, et al. Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema. Retina 2006;26:5-13. 131. Chang PY, Yang CM, Yang CH, et al. Pars plana vitrectomy for diabetic fibrovascular proliferation with and without internal limiting membrane peeling. Eye (Lond) 2009;23:960-965. 132. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007;14:179-183. 133. Younis N, Broadbent DM, Harding SP, et al. Incidence of sight-threatening retinopathy in Type 1 diabetes in a systematic screening programme. Diabet Med 2003;20:758-765. 134. Anderson RE, Rapp LM, Wiegand RD. Lipid peroxidation and retinal degeneration. Curr Eye Res 1984;3:223-227. 135. van Reyk DM, Gillies MC, Davies MJ. The retina: oxidative stress and diabetes. Redox Rep 2003;8:187-192. 136. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007;2007:95103. 137. Yuuki T, Kanda T, Kimura Y, et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications 2001;15:257-259. 138. Harada C, Okumura A, Namekata K, et al. Role of monocyte chemotactic protein-1 and nuclear factor kappa B in the pathogenesis of proliferative diabetic retinopathy. Diabetes Res Clin Pract 2006;74:249-256. 139. Simo-Servat O, Hernandez C, Simo R. Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathy. Mediators Inflamm 2012;2012:872978. 140. Kowluru RA, Koppolu P, Chakrabarti S, et al. Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. Free Radic Res 2003;37:1169-1180. 141. Kowluru RA, Odenbach S. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 2004;53:3233-3238. 142. Kowluru RA, Tang J, Kern TS. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 2001;50:1938-1942. 143. Blokhina O, Virolainen E, Fagerstedt KV. Antioxidants, oxidative damage and oxygen deprivation stress: a review. Ann Bot 2003;91 Spec No:179-194. 144. Kowluru RA, Kern TS, Engerman RL. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. IV. Antioxidant defense system. Free Radic Biol Med 1997;22:587-592. 145. Jackson H, Braun CL, Ernst H. The chemistry of novel xanthophyll carotenoids. Am J Cardiol 2008;101:50D-57D. 146. Kurashige M, Okimasu E, Inoue M, et al. Inhibition of oxidative injury of biological membranes by astaxanthin. Physiol Chem Phys Med NMR 1990;22:27-38. 147. Ohgami K, Shiratori K, Kotake S, et al. Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Invest Ophthalmol Vis Sci 2003;44:2694-2701. 148. Ozawa Y, Sasaki M, Takahashi N, et al. Neuroprotective effects of lutein in the retina. Curr Pharm Des 2012;18:51-56. 149. Nakagawa K, Kang SD, Park DK, et al. Inhibition of beta-carotene and astaxanthin of NADPH-dependent microsomal phospholipid peroxidation. J Nutr Sci Vitaminol (Tokyo) 1997;43:345-355. 150. Oshima S, Ojima F, Sakamoto H, et al. Inhibitory effect of beta-carotene and astaxanthin on photosensitized oxidation of phospholipid bilayers. J Nutr Sci Vitaminol (Tokyo) 1993;39:607-615. 151. Spiller GA, Dewell A. Safety of an astaxanthin-rich Haematococcus pluvialis algal extract: a randomized clinical trial. J Med Food 2003;6:51-56. 152. Stewart JS, Lignell A, Pettersson A, et al. Safety assessment of astaxanthin-rich microalgae biomass: Acute and subchronic toxicity studies in rats. Food Chem Toxicol 2008;46:3030-3036. 153. Nakajima Y, Inokuchi Y, Shimazawa M, et al. Astaxanthin, a dietary carotenoid, protects retinal cells against oxidative stress in-vitro and in mice in-vivo. J Pharm Pharmacol 2008;60:1365-1374. 154. Naguib YM. Antioxidant activities of astaxanthin and related carotenoids. J Agric Food Chem 2000;48:1150-1154. 155. Higuera-Ciapara I, Felix-Valenzuela L, Goycoolea FM. Astaxanthin: a review of its chemistry and applications. Crit Rev Food Sci Nutr 2006;46:185-196. 156. Hussein G, Sankawa U, Goto H, et al. Astaxanthin, a carotenoid with potential in human health and nutrition. J Nat Prod 2006;69:443-449. 157. Izumi-Nagai K, Nagai N, Ohgami K, et al. Inhibition of choroidal neovascularization with an anti-inflammatory carotenoid astaxanthin. Invest Ophthalmol Vis Sci 2008;49:1679-1685. 158. Pashkow FJ, Watumull DG, Campbell CL. Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol 2008;101:58D-68D. 159. Shen H, Kuo CC, Chou J, et al. Astaxanthin reduces ischemic brain injury in adult rats. FASEB J 2009;23:1958-1968. 160. Wu TH, Liao JH, Hou WC, et al. Astaxanthin protects against oxidative stress and calcium-induced porcine lens protein degradation. J Agric Food Chem 2006;54:2418-2423. 161. Uchiyama K, Naito Y, Hasegawa G, et al. Astaxanthin protects beta-cells against glucose toxicity in diabetic db/db mice. Redox Rep 2002;7:290-293. 162. Manabe E, Handa O, Naito Y, et al. Astaxanthin protects mesangial cells from hyperglycemia-induced oxidative signaling. J Cell Biochem 2008;103:1925-1937. 163. Naito Y, Uchiyama K, Aoi W, et al. Prevention of diabetic nephropathy by treatment with astaxanthin in diabetic db/db mice. Biofactors 2004;20:49-59. 164. Speranza L, Pesce M, Patruno A, et al. Astaxanthin treatment reduced oxidative induced pro-inflammatory cytokines secretion in U937: SHP-1 as a novel biological target. Mar Drugs 2012;10:890-899. 165. Suzuki Y, Ohgami K, Shiratori K, et al. Suppressive effects of astaxanthin against rat endotoxin-induced uveitis by inhibiting the NF-kappaB signaling pathway. Exp Eye Res 2006;82:275-281. 166. Yeh PT, Yang CM, Huang JS, et al. Vitreous levels of reactive oxygen species in proliferative diabetic retinopathy. Ophthalmology 2008;115:734-737 e731. 167. Cutler RG. Oxidative stress profiling: part I. Its potential importance in the optimization of human health. Ann N Y Acad Sci 2005;1055:93-135. 168. Levine RL, Garland D, Oliver CN, et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990;186:464-478. 169. Cukiernik M, Mukherjee S, Downey D, et al. Heme oxygenase in the retina in diabetes. Curr Eye Res 2003;27:301-308. 170. Cosso L, Maineri EP, Traverso N, et al. Induction of heme oxygenase 1 in liver of spontaneously diabetic rats. Free Radic Res 2001;34:189-191. 171. Exner M, Minar E, Wagner O, et al. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med 2004;37:1097-1104. 172. Kubo E, Singh DP, Fatma N, et al. TAT-mediated peroxiredoxin 5 and 6 protein transduction protects against high-glucose-induced cytotoxicity in retinal pericytes. Life Sci 2009;84:857-864. 173. Ottaviano FG, Handy DE, Loscalzo J. Redox regulation in the extracellular environment. Circ J 2008;72:1-16. 174. Holmgren A, Lu J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Commun 2010;396:120-124. 175. Gromer S, Urig S, Becker K. The thioredoxin system--from science to clinic. Med Res Rev 2004;24:40-89. 176. Xue J, Thippegowda PB, Hu G, et al. NF-kappaB regulates thrombin-induced ICAM-1 gene expression in cooperation with NFAT by binding to the intronic NF-kappaB site in the ICAM-1 gene. Physiol Genomics 2009;38:42-53. 177. Donadelli R, Abbate M, Zanchi C, et al. Protein traffic activates NF-kB gene signaling and promotes MCP-1-dependent interstitial inflammation. Am J Kidney Dis 2000;36:1226-1241. 178. Bhavsar PK, Sukkar MB, Khorasani N, et al. Glucocorticoid suppression of CX3CL1 (fractalkine) by reduced gene promoter recruitment of NF-kappaB. FASEB J 2008;22:1807-1816. 179. Hernandez C, Segura RM, Fonollosa A, et al. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 2005;22:719-722. 180. Kowluru RA, Kanwar M, Chan PS, et al. Inhibition of retinopathy and retinal metabolic abnormalities in diabetic rats with AREDS-based micronutrients. Arch Ophthalmol 2008;126:1266-1272. 181. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006;109:366-398. 182. Kohda N, Tani T, Nakayama S, et al. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res 1999;96:261-268. 183. Omi H, Okayama N, Shimizu M, et al. Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production. Microvasc Res 2004;68:119-125. 184. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. Jama 2006;295:547-553. 185. Lee JH, Oh GT, Park SY, et al. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 2005;313:502-509. 186. Otsuki M, Saito H, Xu X, et al. Cilostazol repress | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69368 | - |
dc.description.abstract | 玻璃體切除手術目前是增殖性糖尿病視網膜病變各種併發症的主要治療方法之一。以使用現代的手術儀器和技術,手術成功率相當高,從70%到90%不等。成功的關鍵取決於糖尿病視網膜病變疾病發展過程的長短與疾病嚴重程度。手術後,約三分之一手術成功的患者會發生復發性玻璃體出血。出血的原因可能來自殘留的纖維血管組織或是手術後在視網膜周邊形成的新生血管破裂有關。復發性玻璃體出血不僅會延緩病人視力的恢復,還可能會導致需要再次接受手術。因此,若在復雜的糖尿病性玻璃體切除手術中,進行適當的預防性處理程序,以減少術中和術後視網膜出血,這對於預防復發性玻璃體出血是非常重要的。如果術後不幸發生了復發性玻璃體出血,適當的處理可以使新生血管消退,並減少反覆出血的可能性;從而縮短再吸收時間並減少手術需求。在我們的系列研究中,我們設計了一些臨床研究並發展了一些因應不同狀況病人,而有不同處理的有效手術方法,包括(1)術前1週進行玻璃體內bevacizumab(1.25 mg)注射及合併初次矽油灌注;(2)合併玻璃體內bevacizumab注射(1.25 mg)以及視網膜前部冷凍療法來治療糖尿病玻璃體切除術後性玻璃體再次出血;(3)玻璃體內重複注射bevacizumab(1.25 mg)以治療糖尿病視網膜病變經玻璃體切除術後再次出血的患者。我們的結果顯示這些方法對於預防與治療復發性糖尿病玻璃體出血是有效和安全的。
在增殖性糖尿病視網膜病變中,視網膜的纖維血管增生(fibrovascular proliferation)是其獨特的臨床變化;病理上,由於纖維血管增生其複雜的玻璃體與視網膜之間交互關係,頻繁出現的視網膜前膜(epiretinal membrane)和強大的促發炎(proinflammatory)and和促血管生成(pro-angiogenic)環境,進而導致視網膜的病變。視網膜前膜的形成可能發生在各種臨床環境中。它是由視網膜表面的細胞增殖引起的,但是這些增殖細胞的起源目前還是有些爭論。過去,視網膜前膜手術標本中已發現主要有視網膜內膠質細胞(glial cells),其他有視網膜結締組織細胞,甚至也有視網膜色素上皮細胞(retinal pigment epithelial cells)。視網膜前膜形成的病理生理機制在不同疾病情況下可能變化很大。在糖尿病視網膜病變中,視網膜前膜可能在手術前發生,或在成功玻璃體切除術後發生。玻璃體切除術後眼部的特殊狀況,如局部缺血,炎症,出血和纖維血管膜殘留等,都可能使眼睛容易形成術後的視網膜前膜。為了更好地了解視網膜前膜對經過玻璃體切除手術後形成的原因及視網膜前膜移除後對黃斑部結構和預後的影響,我們進行了一項回顧性研究,以評估可能的危險因素,視網膜前膜形態學變化,視覺功能改變以及視網膜前膜移除手術後結果。在此研究中,我們在視網膜前組織中進行組織免疫化學染色研究以明瞭手術後視網膜前膜形成的性質。我們的研究結果顯示,玻璃體切除手術後產生的視網膜前膜是一種複雜的、含不同新生血管密度的組織。這些視網膜前膜通常的表現為廣泛分佈,進展迅速,並會引起黃斑部變形。相關的危險因素包括糖尿病視網膜病變的活動性,嚴重的纖維血管增生,玻璃體手術後出血和纖維血管的殘留。在大多數的情況下,視網膜前膜去除手術是對視力恢復是有益的,而且復發並不少見。 糖尿病病人體內的高血糖會增加了活性氧(reactive oxygen species)的產生並消耗細胞抗氧化的防禦能力,導致氧化壓力(oxidative stress)增強。慢性高氧化壓力被認為是糖尿病視網膜病變的主要原因之一。視網膜因具有高含量的不飽和脂肪酸和高氧攝取,這增加了脂質氧化和活性氧的產生。目前認為這些變化會使視網膜比任何其他組織更容易受到氧化壓力的損傷。 發炎反應可能在糖尿病視網膜病變的發展和進展中起關鍵作用。活性氧是轉錄因子核因子κB(NF-κB)的強刺激物,活性氧會增加細胞激素和趨化介素的轉錄以及增加負責一氧化氮和前列腺素E2的合成酶。所有這些因素都與糖尿病視網膜病變的進展有關。長期以來已知抗氧化劑可抑制發炎反應。在糖尿病視網膜病變的動物模型中,抗氧化劑抑制NF-κB活性,並且抑制白血球駐留和減少白血球生成誘導型一氧化氮合酶(iNOS)。此外,抗氧化劑可抑制糖尿病大鼠中無細胞微血管的形成和避免周細胞(pericytes)細胞核消失的情形。另外,抗氧化劑抑制活性氧的形成並增加抗氧化防禦酶系統的能力。因此,抗氧化劑可能會減少視網膜氧化壓力的生物損傷,減輕發炎程度,並阻止糖尿病視網膜病變的惡化。 藻紅素(astaxanthin)和葉黃素(lutein)都是含有數個雙鍵的羥基類胡蘿蔔素(hydroxycarotenoids)的葉黃素家族。他們可以有效清除活性氧,所以是強力的生物抗氧化劑和抗發炎劑。藻紅素是一種比其他類胡蘿蔔素更有效的抗氧化劑,包括葉黃素,β-胡蘿蔔素,角黃素和玉米黃素。在我們的研究中,我們證明了葉黃素及藻紅素可能經由調節NF-κB活性,減少了糖尿病大鼠模型中的眼部氧化壓力和發炎現象,而有神經保護作用。 西洛他唑(cilostazol)是一種磷酸二酯酶3型(phosphodiesterase 3)抑制劑, 它可以增加細胞內環腺苷一磷酸的濃度,進而減少血小板內的鈣離子,導致抑制血小板聚集及增進血管擴張,最後降低動脈內血壓。有人進一步研究發現西洛他唑(cilostazol)可以減少發炎,改善微循環,而達到對視網膜神經細胞的保護作用。其機轉可能是抑制阿爾法型腫瘤壞死因子(tumor necrosis factor alpha; TNFα)造成的NF-κB活化及其下游的發炎基因的表現。 在我們的研究系列中,我們最初根據增殖性糖尿病視網膜病變的發病機制,發展了新的手術技術來治療糖尿病玻璃體出血。 隨後,我們經由組織切片研究了增殖性糖尿病視網膜病變的獨特組織病理學特徵。最新動物實驗研究顯示,藻紅素及西洛他唑(cilostazol)都是高效抗氧化劑,可以用於預防糖尿病視網膜病變進展並保護眼部功能。 | zh_TW |
dc.description.abstract | Pars plana vitrectomy (PPV) has been one of the major treatments for various complications of proliferative diabetic retinopathy (PDR). With modern instruments and techniques, the anatomical success rate has been quite high, ranging from 70% to 90%, depending upon the severity of the disease process. Post-operatively, about one third of successfully treated patients develop recurrent vitreous hemorrhage (VH). The bleeding may come from residual fibrovascular tissues or may be related to peripherally located postoperative neovascularization. Recurrent VH not only slows visual recovery but also jeopardizes an otherwise successful operation. Therefore, it is crucial to execution of proper preventive managements for reducing intra- and postoperative preretinal hemorrhage in complicated diabetic vitrectomy (DV). If recurrent vitreous hemorrhage occurs postoperatively, appropriate managements might induce regression of neovasculariation and reduce the possibility of repeated bleeding, thus shortening the reabsorption time and reducing the need for surgery. In our serial studies, we designed several clinical studies and developed some effective surgical methods including (1)intravitreal bevacizumab (1.25 mg) injection 1 week before surgery combined primary silicone oil infusion; (2) combination treatment of anterior retinal cryotherapy (ARC) & intravitreal bevacizumab injection (1.25 mg) and (3) repeated intravitreal bevacizumab injection for post-diabetic vitrectomy VH patients to prevent post-diabetic vitrectomy hemorrhage and to treat post-vitrectomy diabetic vitreous hemorrhage. Our results revealed that these methods were effective and safe for treating recurrent diabetic VH.
In PDR, diabetic fibrovascular proliferation (FVP) is unique for its complex vitreoretinal relationship, the frequent presence of epiretinal membrane (ERM) and the strong proinflammatory and pro-angiogenic environment might resulted in PDR. ERM formation may occur in various clinical settings. It results from cellular proliferation along the surface of the retina, but the origin of these proliferating cells has been debated. Intraretinal glial cells, other retinal connective tissue cells, and even retinal pigment epithelial cells have been found in surgical specimens of ERM. The pathophysiology of ERM formation may vary widely in different disease conditions. In diabetic retinopathy, ERM may occur before surgery, or develop after successful vitrectomy. Specific features in the post-vitrectomized eye, such as ischemia, inflammation, hemorrhage, and residual fibrovascular membrane, may predispose the eye to ERM formation. To better understand the effect of the ERM on the macular structure and prognosis after its removal in eyes that have undergone DV, a retrospective study was conducted to evaluate the possible risk factors, morphological changes, visual function changes, and the surgical results of ERM after DV. In addition, immunohistochemical studies were performed in preretinal tissues to elucidate the nature of ERM formation after DV. Our results showed the post-DV ERM is a complex tissue with variable vascularity that often presents with widespread distribution, rapid progression, and causes macular distortion. Associated risk factors include active PDR, high FVP grade, post-DV hemorrhage, and residual fibrovascular stumps. Membrane removal surgery may be beneficial in selected cases, but recurrence is not uncommon. The hyperglycemia that occurs in diabetes increases the production of reactive oxygen species (ROS) and depletes cellular antioxidant defense capacities, resulting in enhanced oxidative stress. Chronic oxidative stress is considered one of the primary causes of diabetic retinopathy. The retina has a high content of unsaturated fatty acids and high oxygen uptake, which increases lipid oxidation and ROS production. This is commonly thought to make the retina more vulnerable than any other tissue to oxidative stress damage. Inflammation may also play a key role in the development and progression of diabetic retinopathy. ROS are strong stimulators of the transcription factor nuclear factor kappa B (NF-κB), which increases the transcription of inflammatory cytokines and chemokines as well as enzymes responsible for nitric oxide and prostaglandin E2 synthesis. All of these factors are involved in the pathogenesis of diabetic retinopathy. Antioxidants have long been known to inhibit inflammatory responses. In animal models of diabetic retinopathy, antioxidants inhibit NF-κB activity, and reduce leukostasis and leukocyte expression of inducible nitric oxide synthase. Moreover, antioxidants can inhibit the formation of cell-free capillaries and generation of pericyte ghosts in diabetic rats. In addition, antioxidants inhibit the formation of ROS and increase the capabilities of the antioxidant defense enzyme system. Therefore, antioxidants might diminish the biologic damage of oxidative stress in the retina, abate the level of inflammation, and arrest the progression of diabetic retinopathy. Astaxanthin (AST) and lutein both are from the xanthophyll family of hydroxycarotenoids which contain several double bonds. They could scavenge ROS to be powerful biological antioxidants and anti-inflammatory agents. AST is a more potent antioxidant than other carotenoids, including lutein, β-carotene, canthaxanthin, and zeaxanthin. In our study, we proved the xanthophyll carotenoid AST had neuroprotective effects and would reduce ocular oxidative stress, and inflammation in the STZ diabetic rat model, which might be mediated by downregulation of NF-κB activity. Cilostazol is a phosphodiesterase 3 (PDE3) inhibitor which has been shown to increase intracellular cyclic adenosine monophosphate levels and then decrease intracellular Ca2+ levels in platelets, resulting in inhibition of platelet aggregation and vasodilation leading to a reduction in arterial pressure. It has been shown to reduce inflammation and improve microcirculation to achieve neuroprotective effects in the retina by inhibiting tumor necrosis factor alpha (TNFα)-induced NF-κB activation and proinflammatory gene expressions. In our study series, we initially developed new surgical techniques according to the pathogenesis of PDR to treat diabetic vitreous hemorrhage. Subsequently, we studied the unique histopathological features of PDR by histologic sections. In the latest study, we applied AST and cilostazol, both are potent antioxidants, to prevent diabetic retinopathy progressing and to preserve ocular functions. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T03:13:56Z (GMT). No. of bitstreams: 1 ntu-107-F98444007-1.pdf: 5976134 bytes, checksum: 8868c37a34fff50d7a0e43cdabd9503a (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 目 錄
論文口試委員會審定書 I 誌謝 II 中文摘要 III 英文摘要 VI Chapter 1: Introduction 1 1.1 Pathogenesis of diabetic retinopathy 1 1.2 Levels of diabetic retinopathy 1 1.3 Surgical approaches to managing PDR 3 A. Panretinal laser photocoagulation (PRP) 3 B. Cryotherapy 4 C. Pars plana vitrectomy 4 D. Intravitreal injection of anti-VEGF drugs 5 1.4 Silicone oils in vitreoretinal surgery 6 Chapter 2. Prevention and treatment for recurrent vitreous hemorrhage in a vitrectomized eye 7 2.1 Pre-operative considerations 7 2.2 Reduction of post-operative VH 8 A. Reduction of vascular injury 9 B. Reduction of vitreous blood and the amount of blood clots at the end of surgery 9 C. Promoting early recovery of injured retinal vessels 17 I. Long-acting gas bubbles may mechanically tamponade and stop bleeding 17 II. Combined bevacizumab pretreatment and silicone oil tamponade 19 D. Preventing the development of NV at the vitreous base, anterior segment, and sclerotomy sites 20 2.3 Management of recurrent VH 24 A. Intravitreal bevacizumab injection for recurrent vitreous haemorrhage after diabetic vitrectomy 26 B. Anterior retinal cryotherapy and intravitreal injection of bevacizumab for nonclearing vitreous hemorrhage in vitrectomized PDR 29 Chapter 3. Preretinal blood and histopathology of epiretinal membrane in proliferative diabetic retinopathy after vitrectomy with silicone oil 35 3.1 Distribution, reabsorption, and complications of preretinal blood under silicone oil after vitrectomy for severe PDR 35 3.2 Clinical and histological features of epiretinal membrane after diabetic vitrectomy 41 Chapter 4. Antioxidants for prevention of diabetic retinopathy 53 4.1 Astaxanthin inhibits expression of retinal oxidative stress and inflammatory mediators in streptozotocin-induced diabetic rats. 54 4.2 Cilostazol attenuates retinal oxidative stress and inflammation in a streptozotocin-induced diabetic animal model 65 參考文獻 73 圖目錄 Figure 1 87 Figure 2 88 Figure 3 89 Figure 4 90 Figure 5 91 Figure 6 92 Figure 7 93 Figure 8 94 Figure 9 95 Figure 10 96 Figure 11 97 Figure 12 98 Figure 13 99 Figure 14 100 Figure 15 101 Figure 16 102 Figure 17 103 Figure 18 104 Figure 19 106 Figure 20 108 Figure 21 109 Figure 22 111 Figure 23 112 Figure 24 113 Figure 25 115 Figure 26 116 Figure 27 117 Figure 28 119 Figure 29 121 Figure 30 122 表目錄 Table 1 123 Table 2 124 附錄 博士班就讀期間糖尿病視網膜病變相關著作 125 博士班就讀期間其他著作 126 | |
dc.language.iso | en | |
dc.title | 糖尿病視網膜病變的臨床治療與病理研究 | zh_TW |
dc.title | Clinical Treatments and Pathological Studies of Diabetic Retinopathy | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 鄭劍廷(Chiang-Ting Chien),楊中美(Chung-May Yang),楊長豪(Chang-Hao Yang),郭冠廷(Kuan-Ting Kuo) | |
dc.subject.keyword | 視網膜前部冷凍治療,藻紅素,癌思停,西洛他唑,血管纖維化增生,氧化壓力,活性氧, | zh_TW |
dc.subject.keyword | anterior retinal cryotherapy,astaxanthin,bevacizumab,cilostazol,diabetic retinopathy,fibrovascular proliferation,oxidative stress,reactive oxygen species, | en |
dc.relation.page | 129 | |
dc.identifier.doi | 10.6342/NTU201801377 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-07-11 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 病理學研究所 | zh_TW |
顯示於系所單位: | 病理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 5.84 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。